Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, August 23, 2022

Remote ischemic conditioning for acute ischemic stroke part 2: Study protocol for a randomized controlled trial

 And all this earlier research was not enough?

The latest here:

Remote ischemic conditioning for acute ischemic stroke part 2: Study protocol for a randomized controlled trial

Kentaro Ishizuka1*, Takao Hoshino1, Sono Toi1, Takafumi Mizuno1, Megumi Hosoya1, Moeko Saito1, Yasuto Sato2, Yoshiki Yagita3, Kenichi Todo4, Manabu Sakaguchi5, Takashi Ohashi6, Kenji Maruyama7, Shuji Hino8, Yutaka Honma9, Ryosuke Doijiri10, Hiroshi Yamagami11, Yasuyuki Iguchi12, Teruyuki Hirano13, Kazumi Kimura14, Takanari Kitazono15 and Kazuo Kitagawa1*
  • 1Department of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
  • 2Department of Public Health, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
  • 3Department of Stroke Medicine, Kawasaki Medical School, Okayama, Japan
  • 4Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
  • 5Department of Neurology, Osaka General Medical Center, Osaka, Japan
  • 6Department of Neurology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan
  • 7Department of Neurology, Toda Chuo General Hospital, Saitama, Japan
  • 8Department of Neurology, Saitama Red Cross Hospital, Saitama, Japan
  • 9Department of Neurology, Showa General Hospital, Tokyo, Japan
  • 10Department of Neurology, Iwate Prefectural Central Hospital, Iwate, Japan
  • 11Department of Stroke Neurology, National Hospital Organization, Osaka National Hospital, Osaka, Japan
  • 12Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan
  • 13Department of Stroke and Cerebrovascular Medicine, Kyorin University, Tokyo, Japan
  • 14Department of Neurology, Nippon Medical School, Tokyo, Japan
  • 15Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Background: Remote ischemic conditioning (RIC) refers to the application of repeated short periods of ischemia intended to protect remote areas against tissue damage during and after prolonged ischemia.

Aim: We aim to evaluate the efficacy of RIC, determined by the modified Rankin Scale (mRS) score at 90 days after stroke onset.

Design and methods: This study is an investigator-initiated, multicenter, prospective, randomized, open-label, parallel-group clinical trial. The sample size is 400, comprising 200 patients who will receive RIC and 200 controls. The patients will be divided into three groups according to their National Institutes of Health Stroke Scale score at enrollment: 5–9, mild; 10–14, moderate; 15–20, severe. The RIC protocol will be comprised of four cycles, each consisting of 5 min of blood pressure cuff inflation (at 200 mmHg or 50 mmHg above the systolic blood pressure) followed by 5 min of reperfusion, with the cuff placed on the thigh on the unaffected side. The control group will only undergo blood pressure measurements before and after the intervention period. This trial is registered with the UMIN Clinical Trial Registry (https://www.umin.ac.jp/: UMIN000046225).

Study outcome: The primary outcome will be a good functional outcome as determined by the mRS score at 90 days after stroke onset, with a target mRS score of 0–1 in the mild group, 0–2 in the moderate group, and 0–3 in the severe group.

Discussion: This trial may help determine whether RIC should be recommended as a routine clinical strategy for patients with ischemic stroke.

Introduction

In recent years, hyperacute reperfusion treatment has progressed remarkably due to the establishment of recombinant tissue-type plasminogen activator (rt-PA) and endovascular treatment (EVT) (1, 2). Although Japan is proceeding with a plan to accelerate the development of an efficient care system for stroke patients (forming new stroke centers and stroke care units), only 6–8% of patients can receive hyperacute reperfusion therapy (3). In Japan, edaravone has been used as an effective method to reduce ischemic insults. However, it is not widely used internationally; it has yet to demonstrate sufficient efficacy (4).

Remote ischemic conditioning (RIC) is a therapeutic strategy in which several cycles of brief focal ischemia, followed by reperfusion in the arms or legs, confer protection against the more severe detrimental effects of ischemia in target organs (58). Although the underlying mechanisms are not fully understood, current evidence indicates that RIC reduces inflammation, oxidative stress, and cerebral edema, mediated by humoral, immunoregulatory, and neurotrophic factors (9). Although the clinical application of RIC in patients with acute ischemic stroke has been attempted, its efficacy has not yet been validated (1012). Moreover, no clinical trials have been conducted on acute ischemic strokes in Japan.

One reason for the inability to confirm the efficacy of RIC in previous studies may be the use of a unified definition of a good outcome as assessed by the modified Rankin Scale (mRS), regardless of the neurological severity of the enrolled patients upon admission. Another reason may be the lack of an established RIC protocol. Therefore, this study aims to evaluate the efficacy of an RIC protocol based on recent literature, determined by the mRS score at 90 days after stroke onset, with a good outcome defined according to the severity at enrollment.

No comments:

Post a Comment